retatrutide triple agonist clinical trial Eli Lilly and Company's agonist, retatrutide, successful in two additional phase 3 obesity trials, delivering significant improvements in weight and A1C Triple hormone receptor agonist retatrutide
Pay in 4 interest-free payments of $7.31 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20


























